SARTORIUS STED BIO (EPA:DIM) Sartorius Stedim Biotech SA: Information on Document Availability
Transparency directive : regulatory news
|
Sartorius Stedim Biotech SA Aubagne, July 19, 2024
Information on Document AvailabilityThe report on the first half 2024 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: It contains the following information:
A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. By the end of 2023, more than 10,600 employees were working for customers around the globe.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 petra.mueller2@sartorius.com
Regulatory filing PDF file File: 2024_SSB_Document availability H1_en |
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report |
| EQS News ID: | 1950133 |
| End of Announcement | EQS News Service |
1950133 19-Jul-2024 CET/CEST
source : webdisclosure.com